A dash of dermatology and a pinch of rheumatology. Sarita Nori, MD, FAAD Dermatology Atrius Health
|
|
- Darlene Morrison
- 5 years ago
- Views:
Transcription
1 A dash of dermatology and a pinch of rheumatology Sarita Nori, MD, FAAD Dermatology Atrius Health
2 I have no conflicts of interest to disclose. 2
3 Points in white = fun factoids Points in blue = important for clinical practice; practice gaps. (Basically what you want to remember from this talk.)
4 Some clinical pearls Treatment Diagnosis Update in Dermatology: OUTLINE Biologics for Psoriasis - because many of your patients are on these meds now. Biologic for Atopic dermatitis finally something new!
5 Treatment pearls For all itch/dermatitis: maximize anti histamines. - Zyrtec/Claritin/Allegra bid, - plus Benadryl or Hydroxyzine qhs, with intent of sedation Poison ivy - Can avoid oral steroids. Use higher topical steroids TID, + maximal anti histamines. - Poison ivy adjunct care: important to dissolve the oil from all objects that may have been exposed. Eg pets, pet collars & leashes, gardening gloves, hats, socks, shoes, watch straps, earrings etc. This is often why the rash seems to get worse despite treatment, or spreads a lot, or recurs even though it was getting better
6 Treatment pearls Tinea versicolor: > treat with Diflucan 400mg po x 2 doses, 1 week apart. Pityriasis Rosea: > Acyclovir 800mg 5 times /day x 1 week => 79% pts cleared by day 14. Das et al. Indian Dermatol Online J May-Jun; 6(3): Seb derm on scalp/psoriasis on scalp/dandruff/itchy scalp: Ketoconazole shampoo daily, clobetasol solution qd for 2-4 weeks Testing in allergy dept is not = skin allergy testing (patch testing). Skin contact allergies develop after multiple exposures, so not usually a new exposure. 6
7 MORE TREATMENT PEARLS Bed bugs/scabies: can cause itching for upto 8 weeks after insects exterminated. Bed bugs: 30% of us will produce no reaction to bed bug bites Eczema/any itchy rash: minimize soap to intertriginous areas only. Avoid fabric softeners altogether. Recommend Eucerin/Aveeno/Cerave calming creams Hair loss: check Ferritin, if < 50, start Fe supplementation for 6 months. Can help hair regrow, no matter the cause.
8 Topical steroid pearls One 80g tube of triamcinolone 0.1% ointment should cover 80% of cases where you would prescribe a topical steroid The other 10% need a larger amount: 454g ( one pound jar ) The other 10% need a less potent steroid (i.e. hydrocortisone 2.5% ointment): eyelids, genitals, babies One tube (or tub if they have a whole body rash) is not going to be enough to give them skin thinning or any long term topical steroid sequelae Why ointments? They don t sting
9 DIAGNOSTIC PEARLS By symptoms By morphology By location
10 DIAGNOSTIC PEARLS By Symptoms Rashes that don t itch: - Tinea versicolor - Pityriasis Rosea - Granuloma Annulare, Sarcoid (these are also more chronic). Painful rashes: > think blood vessels eg vasculitis/chilblains, > or fat panniculitis eg E Nodosum Hives: > itch, > AND always vary/move over 24 hrs. Individual hives do not last more than 24 hrs.
11 DIAGNOSTIC PEARLS Morphology Grouped vesicles/papules = VZV or HSV VZV can span more than 1 dermatome If rash crosses midline, it s NOT VZV HSV recurs at same spot
12 Linear vesicles/vesiculo papules= externally inflicted. Classic culprit is poison ivy.
13 except Lichen Striatus which would be more chronic.
14 DIAGNOSTIC PEARLS Anatomical location Itching in skin folds groin/axillae/penis/web spaces, +/- any bumps = SCABIES until proven otherwise.
15 Neck rashes: induced/complicated by fragrance.
16 Rash on elbows/knees: Psoriasis or Granuloma Annulare.
17 Periumbilical rash: Nickel dermatitis. Recommend clear nail polish on buckles/snaps.
18 Facial Lupus rash - Most butterfly rashes are Rosacea or Seborrheic dermatitis. Think of these first. - Photosensitive, & lack of Rosacea triggers - Scaly - Scarring - Spares naso-labial folds and nasal tip - Other SLE criteria are present
19 Rosacea On cheeks, nose including nasal tip, chin, findings are: Erythema Erythematous papules, sometimes acne like Telangiectasias Clear triggers: alcohol, heat/sunlight, hot foods, spicy foods 19
20 Scaly Spares nasal tip and naso-labial folds On cheeks, nose (including nasal tip), chin: erythema, erythematous papules, telangiectasias 20
21 Rash IN umbilicus: Psoriasis
22 HELIOTROPE RASH A/w Dermatomyositis. Purple eyelids, which are described as heliotrope, as they resemble the heliotrope flower - Heliotropium peruvianum, which has small purple petals.
23 Vs. Eyelid dermatitis (eczematous or contact) Dry Itchy Pinkish red
24 We know a lot about the pathogenesis of Psoriasis! But as of now, no cure in sight 1-4. Keratinocyte TNFα IL-8 (CXCL8) IL-1β IL-6 TNFα Neutrophil IL-17 Mast Cell Myeloid Dendritic Cell Activation IL-23 Keratinocyte IL-17A/F IL-22 GM-CSF Th17 cell T Cells GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin. 1. Res PCM, et al. PLoS One. 2010;5(11):E Lin AM, et al. J Immunol. 2011;187(1): Keijsers RR, et al. Br J Dermatol. 2013;168(6): Taylor PR, et al. Nat Immunol. 2014;15(2):
25 Psoriatic Arthritis Affects 1 in 3 psoriasis patients More common if nails severely affected Can damage and deform joints Pain, limited mobility May limit school/work/recreation Contributes to further reduction in QoL PIP and DIP synovitis Polyarthritis Asymmetric oligoarthritis Dactylitis Spondylitis Arthritis mutilans Enthesitis DIP, distal interphalangeal joint; PIP, proximal interphalangeal joint.
26 To date 10 FDA approved: Anti- TNF: Infliximab (Remicade) Etanercept (Enbrel) Adalimumab (Humira) Golimumab (Simponi) Certolizumab (Cimzia) Anti IL-23/IL-12: Ustekinumab (Stelara) Anti IL-17a: Secukinumab (Cosentyx) Ixekizumab (Taltz) Brodalumab (Siliq) Anti IL-23: Guselkumab (Tremfya) BIOLOGICS for PSORIASIS At least 2 new meds coming out each year 1 non biologic medication: Apremilast (Otezla), the only oral.
27 Apremilast: Oral phosphodiesterase 4 Inhibitor same drug class as Theophylline LPS Proinflammatory Stimuli PG TLR4 GPCR TNF-α IL-23 IL-17 MyD88 IRAK TRAF6 IKKβ IκB NF-κB NF-κB NF-κB CBP Gα s ATP R AC PKA camp PDE-4 AMP AMP P P P p300 CREB CREM ATF-1 Apremilast NF-κB P P P CREB CREM ATF-1 IL-10 PDE-4, phosphodiesterase-4. Schafer P. Biochem Pharmacol. 2012;83(12):
28 So your patient is on a Psoriasis biologic, what do you need to know in clinical practice? IMMUNOSUPPRESSION 1. Infection risk 2. Pre-op clearance 3. Vaccinations 4. Malignancy risk
29 1. INFECTION RISK 1. Aprelimast (anti PDE-4) is not a/w increased risk of infection. 2. Vs the Biologic therapies for Psoriasis, which definitely are. 3. If patients develop serious infections (usually defined as an infection that requires antibiotic therapy) while being treated with a biologic agent, it is prudent to hold the biologic until the infection has resolved*. 4. Anti-TNF s: reactivation of TB, HBV and opportunistic infections fungal, mycobacterial, protozoan. (we screen, and check patients annually with Quantiferon tests). 5. Anti- IL 12/23: viral infections, UTI s, osteomyelitis, diverticulitis, gastroenteritis. 6. Anti-IL 17a: increased candida, HSV. * Amer Acad Derm General principles for patients treated with biologics
30 2. PRE-OP CLEARANCE HOT OFF THE PRESS! 2017 American College of Rheumatology/ American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Anti-rheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Care & Research Vol. 69, No. 8, August 2017, pp Primary Recommendations Governing Anti-Rheumatic Drug Use in Rheumatic disease Patients Undergoing Elective THA or TKA: Non biologic-dmards should be continued in the during and throughout the perioperative period for patients TKA or THA. Biologic therapies should be withheld for surgery and prior to surgery - biologics should be held for one-dosing cycle or surgery should be planned for the end of the dosing cycle of that medication. Biologic therapy that was withheld prior to surgery should be re-started with evidence of wound healing and no sign of infection or drainage (~14 days). There is no need/utility to "stress dose steroids" for those on chronic steroids; the panel recommended the continued use of daily dose of glucocorticoids for patients throughout surgery.
31 EULAR vaccine recommendations 1. Avoid live attenuated vaccines - VZV, nasal flu, MMR 2. For B cell depletion (eg Rituximab): vaccinate before starting Rituximab 3. Do administer flu vaccine (inactivated) 4. Do administer Pneumovax 5. Tetanus recommendation same as general population 6. HPV vaccine should be considered 7. HAV/HBV vaccine only if at risk, and verify immunity 8. Travel recommendation same as general population (live attenuated caveat) Van Assen et al. Ann Rheu Dis 2011;70:
32 4. In patients on biologics, for which malignancies is there evidence for an increased risk? Multiple factors may contribute to risk of cancer in patients with psoriasis 1 Chronic inflammatory nature of disease Increased prevalence of comorbidities associated with cancer risk (eg, smoking, obesity) Potential for increased risk of malignancy with multiple immunosuppressive agents observed in patients with rheumatoid arthritis 2 Recent data suggest increase in risk for selected cancers in patients with psoriasis 3 Increased risk for lymphoma (35%), lung cancer (15%), and nonmelanoma skin cancer (12-20%) vs matched populations without psoriasis Increased risk of Melanoma: controversial, but some registries indicate possible increased risk 1. Pouplard C, et al. J Eur Acad Dermatol Venereol. 2013;27(suppl 3): Strangfeld A, et al. Arthritis Res Ther. 2010;12:R5. 3. Chiesa Fuxench ZC, et al. JAMA Dermatol. 2015;16:1-9.
33 PRACTICE GAP Skin cancer screening for patients on biologics Strong evidence for: increased risk of Non Melanoma Skin Cancer Modest evidence for: increased risk of Melanoma PRACTICE GAP: refer patients on biologics for annual skin checks. Mercer LK, Green AC, Galloway JB, et al The influence of anti-tnf therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register Annals of the Rheumatic Diseases 2012;71: Mercer LK, Askling J, Raaschou P, et al Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers Annals of the Rheumatic Diseases 2017;76:
34 MOC QUESTION What about prior h/o malignancy? The 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis recommends that for patients with RA with a history of low grade melanoma or nonmelanoma skin cancer, therapy with biologics is: a) Completely contra-indicated b) The first choice c) The 2 nd choice after DMARD s d) Acceptable first choice in the setting of moderately or highly active joint disease e) Both C and D Reference: 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research DOI /acr VC 2015, American College of Rheumatology 34
35 Random side effects of biologic meds The medications used to treat Psoriasis can precipitate.psoriasis! MOC question The incidence of anti-tnf therapy induced paradoxical Psoriasis as a cutaneous adverse effect is: a)higher in RA b)higher in IBD patients c) Not reported with Golimumab (Simponi) d)reported with all anti-tnf agents in all conditions treated with anti-tnf therapy. Reference: Dermatological adverse reactions during anti-tnf treatments: Focus on inflammatory bowel disease. Giammarco Mocci Manuela Marzo Alfredo Papa Alessandro Armuzzi Luisa Guidi. Journal of Crohn's and Colitis, Volume 7, Issue 10, 1 November 2013, Pages
36 Random side effects of biologics contd. Autoimmune diseases associated with anti-tnf treatment include a lupus-like syndrome, vasculitis Pulmonary fibrosis anti TNF s Congestive heart failure: anti TNF s R.P.L.S Reversible posterior leukoencephalopathy syndrome, p/w acute onset of confusion, headache, nausea, vomiting, and seizures. Seen w Rituximab (anti B cell) and Ustekinumab (anti IL12/23).
37 Psoriasis patients need your help with their comorbidities: More likely to smoke Have HTN Have diabetes, obesity, and hypercholesterolemia Even when corrected for above risk factors patients with severe psoriasis have an elevated incidence of myocardial infarction compared with age-matched patients without psoriasis Control of HTN, cholesterol, weight, and diabetes can assist in decreasing psoriasis burden and frequency of flares Moderate to severe psoriasis is associated with depression, suicide, this risk increases with disease burden
38 Audience Q&A
39 PEARLS ABOUT SKIN LESIONS: Raised, bumpy, lesions that stick out of the skin are USUALLY benign (eg seb ker s, skin tags, fleshy moles, warts). When a bumpy lesion is a skin cancer (usually BCC/SCC): it s not subtle = bleeds, grows (both in height and diameter) over weeks/days, ulcerates. The danger of melanoma is that it is silent: not itchy, not palpable, doesn t bleed until v advanced, asymptomatic. Fleshy soft bumps on skin, present for yrs, that stick out more from the skin over time = pathognomonic for BENIGN nevii.
Cimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationPsoriatic Arthritis- Secondary Care
Psoriatic Arthritis- Secondary Care Our Psoriatic Arthritis: First Line Treatments information sheet gives information on the treatments that can be prescribed by a GP, or that might be prescribed if the
More informationMedication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014
Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More information2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients
2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients Dr Alberta Hoi Rheumatologist MBBS, FRACP, PhD NEW ERA IN MUSCULOSKELETAL MEDICINE New drugs - Biologics,
More informationPsoriatic Arthritis- Second Line Treatments
Psoriatic Arthritis- Second Line Treatments Second line treatments for Psoriatic Arthritis (PsA) are usually prescribed by a Rheumatologist, Dermatologist, or in a combined clinic where both the Dermatologist
More informationPsoriasis. Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center
Psoriasis Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center Learning objectives Recognize the different types of psoriasis
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationA Patient s Guide to. Treatments for Psoriatic Arthritis
A Patient s Guide to Treatments for Psoriatic Arthritis Who should read this guide? This guide is aimed at people with psoriatic arthritis (abbreviated as PsA), or those who care for a person with this
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
More informationBiologics for Autoimmune Diseases
Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines
More informationTime to Learn. 6 th March 2018 Dr. Shirin Chakera GPwSI Integrated Dermatology Service
Time to Learn 6 th March 2018 Dr. Shirin Chakera GPwSI Integrated Dermatology Service The Red Face Rosacea Acne Seborrhoeic eczema eczema Psoriasis Slapped cheek syndrome Fungal infection Erysipelas...
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 6 Last Review Date: December 8, 2017 Stelara Description Stelara (ustekinumab)
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1017-7 Program Prior Authorization/Notification Medication Cimzia (certolizumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,
More informationRemicade and Friends What You Need to Know Treating the Patient on TNF-alpha Inhibitors and Related Meds
Remicade and Friends What You Need to Know Treating the Patient on TNF-alpha Inhibitors and Related Meds Scott Stienecker MD FACP FSHEA Medical Director for Epidemiology and Infection Prevention Parkview
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationDrugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending
Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2104-4 Program Prior Authorization/Medical Necessity Medication Taltz (ixekizumab) P&T Approval Date 8/2016, 5/2017, 2/2018 Effective
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationBiologic Immunomodulators Prior Authorization with Quantity Limit Program Summary
Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the
More informationPsoriasis. and Biologic Treatments. Choose the best treatment to regain your quality of life. Edition 4
Psoriasis and Biologic Treatments Choose the best treatment to regain your quality of life. Edition 4 PSORIASIS, What is this disease? Psoriasis is a common disease, that affects up to 4% of the population.
More informationDermatology for the frontline
Dermatology for the frontline Kate Foster, D.O. April 28, 2018 Disclaimer: We have consent from patients to use photos for presentation and publication purposes. Please do not take any photos of slides
More informationThe skin is the largest organ of the human body. Functions: protection sensation maintain temperature vitamin synthesis
Dermatology The skin is the largest organ of the human body. Functions: protection sensation maintain temperature vitamin synthesis The image to the left shows an image of skin cells and the proteins which
More informationPharmacy Management Drug Policy
SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationThe GPs role with biologics for immune-mediated inflammatory diseases David Gardner Rheumatologist GPCME 2015
The GPs role with biologics for immune-mediated inflammatory diseases David Gardner Rheumatologist GPCME 2015 The views and opinions expressed in the following presentation are those of the presenter and
More informationSynoviocytes. Macrophage. B cell C H R O N I C. Neutrophil. Mast cell I N F L A M M A T I O N. Tissue cell. Endothelial cell. Th1/Th17 IL17 IL22
DC IL12, IL23 chemokines, ECM, Co-stimulation IL17, IL22 IFNγ ± Macrophage peptidoglycan lipopolysaccharide heat shock proteins Th1/Th17 IL17 IL22 Cell contact, co-stimulation immune complexes acute phase
More informationDermatology Pearls. Leah Layman, ARNP Jefferson Healthcare Dermatology June 21, 2018
Dermatology Pearls Leah Layman, ARNP Jefferson Healthcare Dermatology June 21, 2018 What s on the agenda? Common skin conditions and where to start with treatment Gentle skin care regimen PCP and Biologics
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #337: Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier National Quality Strategy Domain:
More informationRheumatology Therapeutics: Perioperative DMARD Management, Infection and Malignancy Risks, Vaccination Considerations. Heather Hansen, MD
Rheumatology Therapeutics: Perioperative DMARD Management, Infection and Malignancy Risks, Vaccination Considerations Heather Hansen, MD Objectives Know Broad Categories of Rheumatoid Arthritis Medications
More informationRegulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio
More informationSimponi / Simponi ARIA (golimumab)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 6 Last Review Date: September 15, 2016 Simponi / Simponi
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationBiologics and Psoriasis: The Beat Goes On
Biologics and Psoriasis: The Beat Goes On Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Mark Lebwohl is
More informationActemra. Actemra (tocilizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra
More informationPsoriatic arthritis FACTSHEET
1 What is psoriatic arthritis? Psoriatic arthritis (PsA) is a disease where joints around the body become inflamed and sore. It can make moving about difficult and painful. People who have PsA also have
More informationPerioperative Medicine:
Perioperative Medicine: Management of rheumatologic agents Divya Gollapudi, MD May 2016 Medical Operative Consult Clinic Harborview Medical Center Your patient Ms. L is a 55 year-old F w/ h/o RA who presents
More informationPsoriasis. Andrei Metelitsa, MD, FRCPC, FAAD Clinical Associate Professor, Dermatology, U of C Co-Director, Institute for Skin Advancement
Psoriasis Andrei Metelitsa, MD, FRCPC, FAAD Clinical Associate Professor, Dermatology, U of C Co-Director, Institute for Skin Advancement Copyright 2017 by Sea Courses Inc. All rights reserved. No part
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationRheumatoid arthritis and Psoriatic arthritis: a guide for Primary Care. Nina Flavin, MD Rheumatology Confluence Health April 13 th, 2018
Rheumatoid arthritis and Psoriatic arthritis: a guide for Primary Care Nina Flavin, MD Rheumatology Confluence Health April 13 th, 2018 No Disclosures Objectives Recognize early signs of RA/PsA what to
More informationDrug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
More informationMedication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013
Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,
More informationo Your healthcare provider should test you for TB before starting CIMZIA.
Medication Guide CIMZIA (CIM-zee-uh) (certolizumab pegol) lyophilized powder or solution for subcutaneous use Read the Medication Guide that comes with CIMZIA before you start using it, and before each
More informationCOMMON SKIN CONDITIONS IN PRIMARY CARE. Ibrahim M. Zayneh, MD Dermatology Private Practice, Portsmouth, Ohio
COMMON SKIN CONDITIONS IN PRIMARY CARE Ibrahim M. Zayneh, MD Dermatology Private Practice, Portsmouth, Ohio DISCLOSURE The Speaker and members of the planning committee do not have a conflict of interest
More informationPsoriasis. and Biologic Treatments. Choose the best treatment to regain your quality of life.
Psoriasis and Biologic Treatments Choose the best treatment to regain your quality of life. PSORIASIS, What is this disease? Psoriasis is a common disease, that affects up to 4% of the population. It usually
More informationPharmacy Management Drug Policy
SUBJECT: Cimzia (Certolizumab pegol) - for Ankylosing Spondylitis, Crohn s Disease, Psoriatic Arthritis and Rheumatoid Arthritis POLICY NUMBER: PHARMACY-07 EFFECTIVE DATE: 5/2009 LAST REVIEW DATE: 6/13/2018
More informationMEDICATION GUIDE HUMIRA
MEDICATION GUIDE HUMIRA (Hu-MARE-ah) (adalimumab) injection Read the Medication Guide that comes with HUMIRA before you start taking it and each time you get a refill. There may be new information. This
More informationMEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib)
MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib) Read this Medication Guide before you start taking XELJANZ and each time you get a refill. There may be new information. This Medication Guide does not
More informationRashes Not To Be Missed In Children
May 2016 Rashes Not To Be Missed In Children Dr Chan Yuin Chew Dermatologist Dermatology Associates Gleneagles Medical Centre Scope of presentation Focus on rashes May lead to significant morbidity if
More informationSkin Deep: Or is It? Practical Pearls from a Pediatric Dermatologist
Skin Deep: Or is It? Practical Pearls from a Pediatric Dermatologist I have no conflicts of interest 6 yo boy referred for AD. On topical HC and food elimination diet s/p topical triamcinolone to body
More informationPSORIASIS PSORIASIS. Anatomic sites FACTS ABOUT PROSIASIS PSORIASIS 11/16/2017 STIGMATA OF PSORIASIS
PSORIASIS Dr. Sami Alsuwaidan President, Saudi Society of Dermatology & Dermatologic Surgery Associate Professor and Consultant Department of Dermatology, College of Medicine King Saud University PSORIASIS
More informationEXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS
EXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS ACTIVITY 1: EARLY COLLABORATION IN THE TREATMENT OF PSA Key Slides COMMON COMORBIDITIES OF PSORIATIC DISEASE
More informationOutline. Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic. Biologic Drugs. Biologic Drugs. Biologic Drugs Anti-TNF
Outline Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic Types of biologic drugs How do they work? How effective are they? Safety/Toxicity concerns with biologics Biologic
More informationORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Community Plan Medical Benefit Drug Policy ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION Policy Number: CS2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationSteps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS
Moderate to Severe Rheumatoid Arthritis (RA) 3 Steps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS INDICATION/USAGE Adult Rheumatoid Arthritis (RA): ORENCIA (abatacept) is a prescription
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next
More informationRegulatory Status FDA-approved indication: Enbrel and Erelzi are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.27 Subject: Enbrel Page: 1 of 8 Last Review Date: March 16, 2018 Enbrel Description Enbrel (etanercept),
More informationUstekinumab (Stelara )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationHumira. (adalimumab) Drug Update Slideshow NEW INDICATION
Humira (adalimumab) NEW INDICATION Drug Update Slideshow Introduction Brand name: Humira Generic name: Adalimumab Pharmacological class: Tumor necrosis factor (TNF) blocker Strength and Formulation: 10mg/0.2mL,
More informationMEDICATION GUIDE. (tocilizumab)
MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Read this Medication Guide before you start ACTEMRA and before each infusion. There may be new information. This Medication Guide does not take the place
More informationDrug Name (specify drug) Quantity Frequency Strength
Prior Authorization Form GEHA FEDERAL - STANDARD OPTION Autoimmune Conditions (FA-PA) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationRheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW POLAND prof. Małgorzata Wisłowska
Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW 02-507 POLAND prof. Małgorzata Wisłowska MD, PhD 1 Klinika Chorób Wewnętrznych i Reumatologii
More informationPediatric Dermatology. Wingfield Rehmus, MD MPH BC Children s Hospital
Pediatric Dermatology Wingfield Rehmus, MD MPH BC Children s Hospital Conflict of interest! No financial conflict of interest! Individual products shown are examples only not a product endorsement Pediatric
More informationBIOLOGICS THE KEY TO NEXT GENERATION DERMATOLOGY R&D?
White Paper BIOLOGICS THE KEY TO NEXT GENERATION DERMATOLOGY R&D? Clinical trial considerations and best practices TABLE OF CONTENTS Introduction 3 Making a case for biologics 3 Biologic mechanism of action:
More informationDermatology GP Referral Guidelines
Austin Health Dermatology Department holds 5 Clinic sessions to discuss and plan the treatment of with Dermatology conditions. Department of Health clinical urgency categories for specialist clinics Urgent:
More informationA Patient s Guide to Psoriatic Arthritis
A Patient s Guide to Psoriatic Arthritis Glendale Adventist Medical Center 1509 Wilson Terrace Glendale, CA 91206 Phone: (818) 409-8000 DISCLAIMER: The information in this booklet is compiled from a variety
More informationDISCLOSURES. Online A. Infectious Complications of Monoclonal Antibody Therapies 6/22/2012. Cytokine blocking. Lymphocyte depleting.
Online A Infectious Complications of Monoclonal Antibody Therapies Steven M. Holland, M.D. Off-Label Usage None DISCLOSURES Financial Relationships with Relevant Commercial Interests None Resolution: N/A
More informationWhat prescribers need to know
HUMIRA Citrate-free presentations in an Electronic Medical Record (EMR) What prescribers need to know 2 / This is your guide to identifying HUMIRA Citrate-free presentations in your Electronic Medical
More informationINFLAMMATORY BOWEL DISEASE AND SKIN HEALTH KARA N. SHAH, MD, PHD KENWOOD DERMATOLOGY MARCH 4, 2018
INFLAMMATORY BOWEL DISEASE AND SKIN HEALTH KARA N. SHAH, MD, PHD KENWOOD DERMATOLOGY MARCH 4, 2018 DISCLOSURES I HAVE NO RELEVANT FINANCIAL DISCLOSURES INTRODUCTION Structure and function of the skin IBD
More informationJUST FOR KIDS SELECTED IMPORTANT SAFETY INFORMATION
JUST FOR KIDS For children ages 6-17 with moderately to severely active Crohn s disease or ulcerative colitis (UC) who haven t responded well to other therapies SELECTED IMPORTANT SAFETY INFORMATION REMICADE
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority
Quality ID #410: Psoriasis: Clinical Response to Systemic Medications National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes Meaningful Measure Area: Management of Chronic
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationThe Role of Plasmacytoid Dendritic Cells in Psoriasis
6 ème Journée du Groupe de Recherche sur le Psoriasis Paris, 9 novembre 2012 The Role of Plasmacytoid Dendritic Cells in Psoriasis Dr Curdin Conrad, PD & MER Department of Dermatology Psoriasis: Clinical
More informationustekinumab (Stelara )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationSpecialty Pharmacies: What they are. Why they are different.
Specialty Pharmacies: What they are. Why they are different. A changing environment of medicines and pharmacies. Filling a prescription used to be as simple as going to the corner drug store. Today, the
More informationWhy have I been selected for treatment with adalimumab?
ADALIMUMAB What are the aims of this leaflet? This leaflet has been written to help you understand more about adalimumab (Humira TM ). It tells you what it is, how it works, how it is used to treat skin
More informationBlistering, Papulosquamous, Connective Tissue and Alopecia. Kathleen Haycraft, DNP, FNP/PNP-BC, DCNP, FAANP
Blistering, Papulosquamous, Connective Tissue and Alopecia Kathleen Haycraft, DNP, FNP/PNP-BC, DCNP, FAANP Objectives Identify examples of papulosquamous disease and state treatment options Identify examples
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationSubspecialty Rotation: Dermatology
Subspecialty Rotation: Dermatology Faculty: Wesley Galen, M.D. GOAL: Prevention, Counseling and Screening (Dermatology). Understand the pediatrician's role in preventing illness and dysfunction related
More informationMichael P. Heffernan, M.D San Luis Dermatology & Laser Clinic Director, US Probity Medical Research
Michael P. Heffernan, M.D San Luis Dermatology & Laser Clinic Director, US Probity Medical Research mpheffernanmd@gmail.com DISCLOSURES Consultant, Speaker, Investigator: Abbvie, Amgen, Brickell Biotech,
More informationBackground AN UPDATED LOOK AT TREATMENTS FOR PLAQUE PSORIASIS JULY 2018 PLAQUE PSORIASIS TARGETED IMMUNOMODULATORS AS A TREATMENT OPTION
JULY 2018 Background PLAQUE PSORIASIS Plaque psoriasis is a common disease affecting 3% of the US population that causes itchy, red, scaly, raised lesions on the skin, most commonly on the elbows, knees,
More informationcertolizumab pegol (Cimzia )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationRegulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 10 Last Review Date: June 22, 2017 Humira Description Humira (adalimumab),
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationDERMATOLOGY. The Changing Landscape of Psoriasis Treatment ABSTRACT
WHITE PAPER PRESENTED BY PREMIER RESEARCH The Changing Landscape of Psoriasis Treatment ABSTRACT Over the past two decades, biologic therapies have revolutionized the treatment of psoriasis, with more
More informationTreatments used Topical including cleansers and moisturizer Oral medications:
Discipline: Dermatology Extended Topic: Acne & Rosacea : Onset: Location: Face Chest Back Menses if female: Regular Irregular PCOS Treatments used Topical including cleansers and moisturizer Oral medications:
More informationBiologics in Psoriasis. Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre
Biologics in Psoriasis Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre Disclosures Consultancy services for Celgene, Centocor, Almirall, Amgen, Pfizer, Philips,
More informationRecalcitrant Warty Erythroderma With Severe Pruritus. Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University
Recalcitrant Warty Erythroderma With Severe Pruritus Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Gil Yosipovitch,
More informationKEEP UP THE FIGHT WITH. Little Victories
FOR MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA) KEEP UP THE FIGHT WITH Little Victories Small improvements in your daily activities may be a sign that ORENCIA (abatacept) is working for you. Use this
More informationClinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date:
Clinical Policy: (Orencia) Reference Number: ERX.SPA.123 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More information